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Abstract
Background: Cancer cachexia is associated with increased pro-inflammatory cytokine levels. Centella asiatica (C.
asiatica) possesses antioxidant, anti-inflammatory and anti-tumour potential. We investigated the modulation of
antioxidants, cytokines and cell death by C. asiatica ethanolic leaf extract (CLE) in leukaemic THP-1 cells and normal
peripheral blood mononuclear cells (PBMC’s).
Methods: Cytotoxcity of CLE was determined at 24 and 72 h (h). Oxidant scavenging activity of CLE was evaluated
using the 2, 2-diphenyl-1 picrylhydrazyl (DPPH) assay. Glutathione (GSH) levels, caspase (−8, −9, −3/7) activities and
adenosine triphosphate (ATP) levels (Luminometry) were then assayed. The levels of tumour necrosis factor-α
(TNF-α), interleukin (IL)-6, IL-1β and IL-10 were also assessed using enzyme-linked immunosorbant assay.
Results: CLE decreased PBMC viability between 33.25–74.55% (24 h: 0.2–0.8 mg/ml CLE and 72 h: 0.4–0.8 mg/ml CLE)
and THP-1 viability by 28.404% (72 h: 0.8 mg/ml CLE) (p < 0.0001). Oxidant scavenging activity was increased by CLE
(0.05–0.8 mg/ml) (p < 0.0001). PBMC TNF-α and IL-10 levels were decreased by CLE (0.05–0.8 mg/ml) (p < 0.0001).
However, PBMC IL-6 and IL-1β concentrations were increased at 0.05–0.2 mg/ml CLE but decreased at 0.4 mg/ml
CLE (p < 0.0001). In THP-1 cells, CLE (0.2–0.8 mg/ml) decreased IL-1β and IL-6 whereas increased IL-10 levels (p < 0.
0001). In both cell lines, CLE (0.05–0.2 mg/ml, 24 and 72 h) increased GSH concentrations (p < 0.0001). At 24 h,
caspase (−9, −3/7) activities was increased by CLE (0.05–0.8 mg/ml) in PBMC’s whereas decreased by CLE (0.2–0.
4 mg/ml) in THP-1 cells (p < 0.0001). At 72 h, CLE (0.05–0.8 mg/ml) decreased caspase (−9, −3/7) activities and ATP
levels in both cell lines (p < 0.0001).
Conclusion: In PBMC’s and THP-1 cells, CLE proved to effectively modulate antioxidant activity, inflammatory
cytokines and cell death. In THP-1 cells, CLE decreased pro-inflammatory cytokine levels whereas it increased
anti-inflammatory cytokine levels which may alleviate cancer cachexia.
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Background
The role of inflammation in carcinogenesis has been
extensively documented [1]. Although inflammatory re-
sponses have shown beneficial effects in tissue repair
and pathogen elimination [1, 2], chronic inflammation
has been implicated in tumour initiation, promotion
and progression [3]. During ideal conditions, the host-
mediated anti-tumour activity combats the tumour-
mediated immunosuppressive activity and cancerous
cells are sentenced to cell death [3]. In the event that
the host anti-tumour activity is weakened/inadequate,
the persistent and enhanced pro-inflammatory tumour
microenvironment will facilitate tumour development,
invasion, angiogenesis and metastasis [3].
Many malignancies are associated with the cachectic
syndrome [4], a disorder characterised by abnormal
weight loss [5] due to adipose tissue (85%) and skeletal
muscle (75%) depletion [6]. The enzyme lipoprotein lipase
(LPL) hydrolyses fatty acids (FA’s) and transports FA’s into
adipose tissue for triacylglycerol (TAG) production,
whereas hormone sensitive lipase (HSL) breaks down
TAG’s into FA’s and glycerol [6]. Studies have revealed that
decreased serum LPL levels/activity [7, 8] and increased
HSL levels/activity are associated with cachexia [9].
Additionally, increased proteolysis and decreased proteo-
genesis have been reported in cachectic patients [10]. The
ATP-ubiquitin-dependent proteolytic pathway has been
shown to be responsible for the excessive proteolysis seen
in cancer cachexia [11].
Oxidative stress, inflammatory cytokines and apop-
tosis play a pivotal role in the initiation and develop-
ment of cancer cachexia [12]. Inflammatory cytokine
production is increased by lipopolysaccharide (LPS)
potently stimulating macrophages [13]. The LPS
signal is transduced by LPS binding to LPS binding
protein, delivered to CD14 and transferred to Toll
like receptor-4 [14]. This subsequently activates nu-
clear factor kappa B (NF-κB), which regulates the
transcription of genes associated with inflammation, pro-
liferation, invasion, angiogenesis and apoptosis [1, 15–17].
Previously, IL-1 [18], IL-6 (mice) [19] and TNF-α (rat,
mouse and guinea pigs) [20] were shown to decrease LPL
activity in adipose tissue. Decreased LPL activity reduces
the uptake of exogenous lipids by adipose tissue [20],
which decreases lipogenesis. Additionally, previous
literature showed that TNF-α increased ubiquitin
(concentrations and mRNA), while IL-6 increased the
26S proteasome and cathepsin activities, suggesting the
activation of proteolytic pathways [21–24]. The activa-
tion of proteolytic pathways causes extensive muscle
wasting through proteolysis. Taken together, an excessive
increase in pro-inflammatory cytokine levels may increase
tumour immunosuppressive activity [3], as well as tissue
wasting [6].
Oxidative stress has been associated with tumour ini-
tiation, inflammation [2, 3] and muscle wasting [25].
However, antioxidants have been shown to decrease
muscle wasting by neutralizing reactive oxygen species
(ROS) [1, 25]. Elevated ROS levels activate apoptotic
pathways, ultimately activating caspase-3 [26]. The acti-
vation of caspase-3 plays an important role in the exe-
cution of apoptosis as well as muscle proteolysis [27].
Additionally, in weight-losing upper gastrointestinal
tract cancer patients, deoxyribonucleic acid (DNA)
fragmentation and poly (ADP-ribose) polymerase (PARP)
cleavage were increased, whereas MyoD protein was de-
creased [6], suggesting increased apoptosis and decreased
muscle replenishment.
There is a constant need for alternative traditional
medicines to improve the prognosis of cancer patients
and prevent chemotherapy and radiotherapy induced
discomfort. The tropical medicinal plant Centella
asiatica (Linnaeus) Urban (C. asiatica) is native to
India, China, and South Africa [28]. It belongs to the
Apiaceae family and is commonly referred to as Gotu
kola, Asiatic pennywort and Tiger herb [28]. C. asiatica
is widely used in Ayurvedic and Chinese traditional
medicines due to its various medicinal properties.
These properties include its hepato-protective, cardio-
protective, anti-diabetic, antioxidant, anti-inflammatory
and anti-tumour potential [28]. The major active com-
pounds in C. asiatica are triterpene saponosides such as
asiatic acid, madecassic acid and asiaticoside [28]. C. asia-
tica also contains flavonoid derivatives, vitamins, minerals,
polysaccharides, sterols and phenolic acids [28]. C. asia-
tica has previously been used in treatment of inflamma-
tion due to its promising anti-inflammatory effects [29,
30]. Additionally, C. asiatica extracts have demonstrated
high antioxidant [31, 32] and anti-proliferative activity in
many cancerous cell lines [33].
There is a need for the discovery of an inexpensive
cancer cachectic treatment. The ability of a plant extract
to regulate inflammatory cytokines and cell death may
elevate cancerous cell death and diminish tissue wasting.
We investigated the potential of a C. asiatica ethanolic
leaf extract (CLE) to modulate inflammatory cytokines,
antioxidants and cell death in leukaemic THP-1 cells and
normal peripheral blood mononuclear cells (PBMC’s).
Methods
Materials
C. asiatica leaves were collected on the 7th of March
2011 (collectors number: Immelman 411) from the
Eastern Cape [Langeni forest, roadside (S31°28.135′,
E28°32.681′)], South Africa (SA) and identified by Dr.
Kathleen Immelman from the Department of Botany at
the Walter Sisulu University, SA. Voucher specimens were
deposited at the KEI herbarium (13979). The THP-1 cells
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were obtained from American Type Culture Collection
(ATCC, University Boulevard Manassas, Virginia, USA).
RPMI-1640 and BD OptEIA enzyme-linked immunosor-
bant assay (ELISA) cytokine kits were purchased from
The Scientific Group (Johannesburg, SA). Foetal calf
serum (FCS) and Pen/Strep Amphotericin B (PSF) were
acquired from Whitehead Scientific (Cape Town, SA).
Dimethyl sulphoxide (DMSO) was purchased from Merck
(Johannesburg, SA). Histopaque-1077, LPS and 2, 2-
diphenyl-1 picrylhydrazyl (DPPH) were purchased from
Sigma (Aston Manor, SA). The 4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate
(WST-1) cell proliferation reagent was purchased from
Roche (Johannesburg, SA). Promega (Madison, USA) sup-
plied the caspase (−3/7, −8, −9), adenosine triphosphate
(ATP) and glutathione (GSH) kits.
Plant description and extraction
The plants official name is Centella asiatica (L.) Urb
and has been confirmed by using the plant list [34]. The
English name is Tiger herb. C. asiatica leaves were dried
and milled. Ethanol (200–350 ml) was added to milled
plant material (10–30 g) and extracted overnight by
shaking (4×g, 37 °C). Ethanol extracts were filtered, rotor
evaporated, dried (37 °C) and stored (4 °C).
The 2, 2-diphenyl-1 picrylhydrazyl assay
CLE (0.05–0.8 mg/ml) and butylated hydroxytoluene
(BHT) (60–300 μM) dilutions were prepared in methanol
(99.5% and grade AR). A 50 μM DPPH solution was pre-
pared from a stock solution of 0.135 mM DPPH in metha-
nol. CLE, BHT dilutions and methanol (1 ml, triplicate
tubes) were aliquoted into 15 ml polypropylene tubes,
followed by the 50 μM DPPH solution (1 ml). Reaction
mixtures were vortexed and incubated (room temperature
(RT) for 30 min (min)) in the dark. Absorbance of samples
was read at 517 nm using a Varine Cary 50 UV-visible
spectrophotometer (McKinley Scientific, New Jersey, US).
Isolation of peripheral blood mononuclear cells
Buffy coats containing PBMC’s were obtained from the
South African National Blood Service (2011/09). PBMC’s
were extracted by differential centrifugation. Buffy coats
(5 ml) were layered onto equivolume histopaque-1077
(5 ml) in 15 ml polypropylene tubes and centrifuged
(400×g, 21 °C for 30 min). After centrifugation, the
PBMC’s were transferred to sterile 15 ml polypropylene
tubes, phosphate buffered saline (PBS) was added (0.1 M,
10 ml) and tubes were centrifuged (400×g, 21 °C, 15 min).
Cell density of isolated PBMC’s was adjusted (1 × 106
cells/ml) using the trypan blue exclusion test and cryo-
preserved (10% FCS, 10% DMSO) using a NELGENE cryo
freezing container and stored at −80 °C.
Tissue culture
THP-1 cells were grown in the appropriate tissue culture
conditions in a 75 cm3 tissue culture flask (37 °C, 5%
CO2). The growth media comprised of RPMI-1640, FCS
(10%) and PS (2%). Cells were thawed, seeded into a
75 cm3 tissue culture flask at a concentration of 3 × 105
cells/ml and incubated (37 °C, 5% CO2). THP-1 cells were
allowed to grow for 2–3 days before the cells were centri-
fuged (162×g, 10 min) and re-suspended in fresh growth
media. The number of cells should not exceed 8 × 105
cells/ml, therefore the cells/ml was quantified daily by
trypan blue staining. Once the cell count reached 8 × 105
cells/ml the THP-1 cells were split/ diluted to 3 × 105
cells/ml with media and incubated. Subsequent experi-
ments were conducted once the cell numbers were
sufficient.
Cell viability assay
Cytotoxicity of CLE in PBMC’s and THP-1 cells was
measured using the WST-1 assay (Roche, Johannesburg,
SA). PBMC and THP-1 cells (10,000 cells/well, 96-well
plate, in triplicate wells) were stimulated with LPS
(20 μg/ml, 37 °C, 5% CO2, 4 h (h)) before exposure to
CLE (0.05–0.8 mg/ml) for 24 and 72 h (37 °C, 5% CO2).
Similarly, controls received media containing DMSO
(0.2%). Thereafter, plates were centrifuged (162×g,
10 min), supernatant removed, cell pellets re-suspended
in growth media (100 μl/well), WST-1 reagent (10 μl/
well) added and plates incubated (37 °C, 5%, CO2, 3 h).
Optical density was measured at 450 nm (620 nm refer-
ence wavelength) with a BIO-TEK μQuant spectropho-
tometer (Analytical and Diagnostic Products, SA). This
experiment was conducted independently on three
occasions.
Stimulation and treatment of cells
PBMC’s and THP-1 cells (1 × 105 cells/ml) were trans-
ferred into 24-well plates, stimulated with LPS (20 μg/ml,
37 °C, 5% CO2, 4 h) before exposure to CLE (0.05–0.8 mg/
ml) for 24 h (TNF-α) and 72 h (IL-1β, IL-6, IL-10) (37 °C,
5% CO2). After incubation, plates were centrifuged
(162×g, 10 min) and supernatant was collected and stored
(−80 °C) for cytokine analysis. Cell pellets were used to
conduct the caspase (−8, −9, −3/7) activity, ATP and GSH
assays. The experiments were conducted independently
(twice for all subsequent assays).
Quantification of cytokines
Cytokine levels were estimated using the BD OptEIA
ELISA kits (The Scientific Group, SA) and the procedure
was followed as per the instruction manual. ELISA plates
were coated with capture antibody overnight (100 μl/
well, 4 °C). Thereafter, plates were washed (3×) with
wash buffer and blocked with assay diluent (200 μl/well,
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1 h, RT). Standard solutions were prepared by diluting a
stock solution [TNF-α, IL-10 (500 pg/ml), IL-6
(300 pg/ml), IL-1β (250 pg/ml)] serially [TNF-α, IL-10
(500–7.8 pg/ml), IL-6 (300–4.7 pg/ml), IL-1β (250–
3.9 pg/ml)]. Plates were washed (3×), standards and
samples (100 μl/well, triplicate wells) were aliquoted
into appropriate wells and plates were incubated (2 h,
RT). Plates were washed (5×), working detector (100 μl/
well) added and plates incubated (1 h, RT). The plates
were washed (7×), substrate solution (100 μl/well) added
and plates were incubated (30 min, RT) in the dark.
Finally, stop solution (50 μl/well) was added and the
absorbance was read at 450 nm (570 nm reference wave-
length) with a Multiskan FC micro-plate reader (Thermo
Scientific). Cytokine concentrations were calculated by
extrapolation from a standard curve.
Glutathione assay
The GSH-Glo™ assay (Promega, Madison, WI, USA)
was used to measure GSH levels. Standard GSH solu-
tions were prepared by diluting a 5 mM stock solution
serially (1.56–50 μM) and PBS (0.1 M) was the standard
blank. Cells (50 μl/well, 2 × 105 cells/ml) and standards
were added into an opaque 96-well plate (duplicate
wells), followed by GSH-Glo™ reagent (25 μl/well) and
allowed to incubate (30 min, RT) in the dark. Subse-
quently, luciferin detection reagent (50 μl/well) was
added and plates incubated (15 min, RT) in the dark.
The absorbance was read on a Modulus™ microplate
luminometer (Turner Biosystems, Sunnyvale, USA) and
GSH concentrations were calculated by extrapolation
from a standard curve.
Caspase and ATP assays
Caspase activity and ATP levels were determined
using the Caspase-Glo®-3/7, −8, −9 and ATP assay kits
(Promega, Madison, WI, USA). Caspase-Glo®-3/7, −8,
−9 and ATP reagents were reconstituted according to
the manufacturer’s instructions. Cells (100 μl, 2 × 105
cells/ml) were added into duplicate wells of a microti-
tre plate for each assay, thereafter caspase −3/7, −8,
−9 and ATP reagents (100 μl/well) were added into
appropriate wells. The plate was incubated (30 min,
RT) in the dark. Luminescence was measured on a
Modulus™ microplate luminometer (Turner BioSys-
tems) and expressed as relative light units (RLU).
Statistical analysis
Statistical analysis was performed using the STATA and
GraphPad Prism (v5) statistical analysis software. The
one-way analysis of variance (ANOVA) was used to
make comparisons between groups, followed by the
Tukey multiple comparisons test, with p < 0.05 indicat-
ing significant results.
Results
The oxidant scavenging potential of CLE
The oxidant scavenging activity of CLE using the DPPH
assay is shown in Fig. 1. CLE (0.05–0.8 mg/ml) signifi-
cantly increased DPPH scavenging activity by approxi-
mately 45–84% (Fig. 1, p < 0.0001).
The in vitro cytotoxicity of CLE
The WST-1 assay was used to determine cell viability
of THP-1 cells and PBMC’s after treatment with CLE
(Fig. 2). At 24 h, CLE (0.2–0.8 mg/ml) dose dependently
decreased PBMC viability by 33.25–61.85% (Fig. 2a,
p < 0.0001), whereas THP-1 viability was not signifi-
cantly altered as compared to the control (Fig. 2c, p =
0.0003). At 72 h, CLE decreased both PBMC (Fig. 2b,
34.268–74.547%) and THP-1 (Fig. 2d, czmg/ml respect-
ively as compared to the control (p < 0.0001), suggesting
that PBMC’s are more sensitive to CLE treatment than
THP-1 cells.
The immune suppressive properties of CLE
CLE altered cytokine levels in PBMC’s and THP-1 cells
which are shown in Figs. 3 and 4 respectively. The levels
of TNF-α, IL-1β, IL-6 and IL-10 produced in LPS stimu-
lated PBMC’s was 309.60, 152.83, 626.33 and 23.55 pg/
ml respectively. CLE (0.05–0.2 mg/ml) increased PBMC
IL-1β and IL-6 concentrations relative to the control
(Fig. 3b–c, p < 0.0001). In PBMC’s, TNF-α, IL-1β and
IL-6 concentrations were decreased at 0.05–0.8 mg/ml
CLE, 0.4–0.8 mg/ml CLE and 0.4 mg/ml CLE respectively
as compared to the control (Fig. 3a–c, p < 0.0001). The
levels of TNF-α, IL-1β, IL-6 and IL-10 produced in LPS
stimulated THP-1 cells was 5.96, 25.92, 98.63, and
2.46 pg/ml respectively. TNF-α concentration in THP-1
cells was increased by CLE (0.05, 0.8 mg/ml, Fig. 4a, p <
0.0001) relative to the control. In THP-1 cells, IL-1β and
Fig. 1 Percentage DPPH scavenging activity of CLE (Values expressed
as mean ± SD, ***p < 0.0001 compared to control)
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Fig. 2 Cell viability of PBMC (a – 24 h, b – 72 h) and THP-1 (c – 24 h, d – 72 h) cells treated with CLE for 24 and 72 h (Values expressed as
mean ± SD, ** p < 0.001, *** p < 0.0001 compared to the control)
Fig. 3 Concentration of TNF-α (a), IL-1β (b), IL-6 (c) and IL-10 (d) in CLE treated PBMC’s (Values expressed as mean ± SD, *p < 0.01, *** p < 0.0001,
compared to the control)
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IL-6 concentrations were increased by 0.05 mg/ml CLE
whereas decreased by 0.2–0.8 mg/ml CLE as compared
to the control (Fig. 4b–c, p < 0.0001). Concentration
of the anti-inflammatory cytokine, IL-10 was de-
creased in PBMC’s while increased in THP-1 cells by
CLE (0.05–0.8 mg/ml) relative to the control (Figs. 3d
and 4d, p < 0.0001).
The antioxidant potential of CLE
The endogenous antioxidant activity of CLE was deter-
mined by measuring GSH levels in both cell lines (Table
1). At 24 h, GSH levels in PBMC’s were increased by
0.05–0.2 mg/ml CLE but decreased by 0.4–0.8 mg/ml
CLE relative to the control (Table 1, p < 0.0001). In
THP-1 cells, CLE (0.05–0.8 mg/ml) increased GSH levels
as compared to the control (Table 1, 24 h, p < 0.0001).
At 24 h, GSH concentrations were increased to a greater
extent in THP-1 cells (0.068–3.890 μM) than PBMC’s
(0.191–1.746 μM). At 72 h, CLE (0.05–0.8 mg/ml)
increased GSH concentrations in PBMC’s and THP-1
cells by 1.13–5.91 μM and 0.12–0.19 μM respectively as
compared to the control (Table 1, p < 0.0001). Notably,
CLE increased GSH levels to a greater extent in PBMC’s
as compared to THP-1 cells at 72 h.
CLE modulates caspase (−8, −9, −3/7) activities and ATP
levels
Luminometry assays were used to determine caspase
activity and ATP levels in THP-1 cells and PBMC’s
after treatment with CLE. The pro-apoptotic effect of
Fig. 4 Concentration of TNF-α (a), IL-1β (b), IL-6 (c) and IL-10 (d) in CLE treated THP-1 cells (Values expressed as mean ± SD, ** p < 0.001, ***
p < 0.0001 compared to the control)
Table 1 Glutathione levels in CLE treated PBMC’s and THP-1 cells
Glutathione (μM)
CLE (mg/ml) 24 h treatment 72 h treatment
PBMC THP-1 PBMC THP-1
Control 1.238 ± 0.007 1.713 ± 0.002 3.842 ± 0.009 1.449 ± 0.002
0.05 1.429 ± 0.007*** 4.125 ± 0.004*** 9.138 ± 0.082*** 1.576 ± 0.007***
0.2 2.984 ± 0.004*** 5.603 ± 0.004*** 4.972 ± 0.003*** 1.568 ± 0.007***
0.4 0.959 ± 0.002*** 1.781 ± 0.002*** 5.534 ± 0.011*** 1.610 ± 0.009***
0.8 1.073 ± 0.015*** 2.495 ± 0.005*** 9.749 ± 0.015*** 1.634 ± 0.004***
(Values expressed as mean ± SD, ***p < 0.0001, compared to the control)
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CLE in PBMC’s treated for 24 h is shown in Table 2. At
24 h, PBMC caspase-8 activity was increased by 0.05–
0.2 mg/ml CLE, whereas decreased by 0.4–0.8 mg/ml
CLE as compared to the control (Table 2, p < 0.0001).
CLE (0.05–0.8 mg/ml, 24 h) increased PBMC caspase
−9 and −3/7 activities relative to the control (Table 2,
p < 0.0001). Increased caspase activity led to the initi-
ation and execution of PBMC apoptosis at 24 h. The
PBMC ATP levels were increased by 0.4 mg/ml CLE,
whereas decreased by 0.05, 0.2 and 0.8 mg/ml CLE
(Table 2, p < 0.0001).
CLE pro-apoptotic effects in THP-1 cells treated for
24 h is shown in Table 3. At 24 h, CLE (0.05–0.8 mg/
ml) increased THP-1 caspase-8 activity as compared
to the control (Table 3, p < 0.0001). In THP-1 cells,
caspase-9 activity and ATP levels were decreased by
0.05–0.4 mg/ml CLE, whereas increased by 0.8 mg/ml
CLE relative to the control (Table 3, 24 h,
p < 0.0001). The THP-1 caspase-3/7 activity was de-
creased by 0.2–0.4 mg/ml CLE, whereas increased by
0.05 and 0.8 mg/ml CLE as compared to the control
(Table 3, 24 h, p < 0.0001). THP-1 caspase (−8, −9,
−3/7) activities was increased by 0.8 mg/ml CLE, sug-
gesting an increased initiation and execution of THP-
1 apoptosis.
The pro-apoptotic effect of CLE in PBMC’s treated for
72 h is shown in Table 4. At 72 h, PBMC caspase-8
activity was increased by 0.4 mg/ml CLE, whereas
decreased by 0.05, 0.2, 0.8 mg/ml CLE relative to the
control (Table 4, p < 0.0001). CLE (0.05–0.8 mg/ml) de-
creased PBMC caspase (−9, −3/7) activities and ATP
levels as compared to the control (Table 4, 72 h,
p < 0.0001). Decreased PBMC caspase activity suggests
a decrease in PBMC apoptotic cell death.
CLE pro-apoptotic effects in THP-1 cells treated for
72 h is shown in Table 5. At 72 h, THP-1 caspase-8
activity was increased by 0.4 mg/ml CLE whereas
decreased by 0.05, 0.2, 0.8 mg/ml CLE relative to the
control (Table 5, p < 0.0001). CLE (0.05–0.8 mg/ml) de-
creased THP-1 caspase (−9, −3/7) activities and ATP
levels as compared to the control (Table 5, 72 h,
p < 0.0001). Decreased THP-1 caspase activity suggests
a decrease in THP-1 apoptotic cell death.
Discussion
Cancer and cachexia have been associated with increased
levels of oxidative stress, pro-inflammatory cytokines and
apoptosis [6, 27]. The medicinal plant, C. asiatica pos-
sesses anti-inflammatory [29] and anti-tumor activity [35],
which can be beneficial in the treatment of cancer
cachexia.
Previously, Zainol et al. (2003) reported that C. asiatica
possessed antioxidant potential, possibly associated with
phenolic compounds [36]. The DPPH assay revealed that
CLE has oxidant scavenging potential ranging between 45
and 84% at 0.05–0.8 mg/ml CLE. ROS plays a pivotal role
in tumour initiation, inflammation, protein degradation
and apoptosis. The significant oxidant scavenging poten-
tial of CLE may decrease inflammatory cytokine levels and
ROS induced apoptosis.
At 24 h, CLE dose dependently decreased PBMC via-
bility, whereas THP-1 viability remained unchanged.
However, at 72 h, CLE significantly decreased both
PBMC and THP-1 viability. C. asiatica derived com-
pounds, asiatic acid and asiticoside, were shown to reduce
RAW 264.7 cell viability (120 μM, 24 h) by 82% and 71%
respectively [37]. Additionally, C. asiatica extracts inhib-
ited breast (MCF-7) and liver (HepG2) cancer cell prolif-
eration [33, 38], indicating our data on CLE cytotoxicity is
in agreement with previous studies.
Inflammatory cytokines play an essential role in
tumourgenesis and the cachectic syndrome [6]. Previously,
Punturee et al. (2004) reported that C. asiatica ethanolic
extract modulated/suppressed TNF-α production in
mouse macrophages [39]. Our results also show that CLE
decreased TNF-α concentration in PBMC’s. Yun et al.
(2008) reported that the pre-treatment of RAW264.7 cells
with asiatic acid significantly reduced IL-6 production
with minimal effects on TNF-α and IL-1β levels [37]. Our
findings, however, suggest that CLE modulates pro-
inflammatory cytokine levels. In both PBMC’s and THP-1
cells, IL-1β and IL-6 levels were increased by the lower
0.05 mg/ml CLE concentration but decreased at the higher
0.4 mg/ml CLE concentration. Pro-inflammatory cytokines,
over a chronic time period, stimulate the production of
genotoxic molecules [nitric oxide (NO), ROS] and tumour
progression by promoting angiogenesis and metastasis
Table 2 Modulation of caspase (−8, −9, −3/7) activities and ATP levels in 24 h CLE treated PBMC’s
CLE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 0.146 ± 0.001 0.265 ± 0.002 5.861 ± 0.028 3.486 ± 0.011
0.05 0.176 ± 0.001*** 0.293 ± 0.001*** 6.066 ± 0.032 3.168 ± 0.006***
0.2 0.256 ± 0.003*** 0.364 ± 0.002*** 6.264 ± 0.031** 3.074 ± 0.002***
0.4 0.135 ± 0.001*** 0.397 ± 0.0003*** 16.407 ± 0.263*** 4.180 ± 0.013***
0.8 0.101 ± 0.001*** 0.307 ± 0.0004*** 6.331 ± 0.007*** 0.796 ± 0.002***
(Values expressed as mean ± SD, **p < 0.001, ***p < 0.0001 compared to the control)
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[1, 3]. Previous literature has shown that IL-1 stimu-
lates malignant cell growth and invasiveness [3]. In
addition, IL-6 exerts its tumour proliferative and anti-
apoptotic potential by targeting genes involved in cell
cycle progression and the suppression of apoptosis
[3]. The ability of CLE to increase pro-inflammatory
cytokines such as IL-1β in PBMC’s may aid in cancerous
cell elimination through increased host anti-tumour activ-
ity. Conversely, in THP-1 cells, the decrease in IL-6 and
IL-1β concentrations by CLE may diminish cytokine in-
duced tumour immunosuppressive activity and cancer
progression.
With regard to the cachectic syndrome, TNF-α in-
hibits the production of LPL and reduces the rate of
LPL gene transcription [40–42], thereby preventing the
formation of new lipid stores while stimulating HSL and
increasing lipolysis [43]. In adipose tissue (in vivo), IL-6
decreased LPL activity leading to tissue wasting in cach-
ectic individuals [19]. The potential of CLE (0.4 mg/ml)
to decrease IL-6 and IL-1β concentrations in PBMC’s
and THP-1 cells suggests a decrease in LPL inhibition
and HSL stimulation, thus contributing to lipogenesis
maintenance and minimal lipolysis. IL-6 and TNF-α
further contribute to cachexia by stimulating muscle
catabolism through the activation of the ubiquitin-
proteasome pathway [21, 22, 44]. Furthermore, pro-
inflammatory cytokines activate NF-κB which regulates
the expression of genes involved in the suppression of
tumour apoptosis, stimulation of tumour cell cycle pro-
gression and enhancement of inflammatory mediators
[1, 3]. Taken together, NF-κB promotes tumour progres-
sion, invasion, angiogenesis and metastasis [1, 3]. In
cachexia, NF-κB activation induces ubiquitin–prote-
asome pathway activity and suppresses MyoD expression
[45], thereby increasing proteolysis and decreasing muscle
replenishment [46]. By decreasing IL-6 and IL-1β concen-
trations in PBMC’s and THP-1 cells, CLE (0.4 mg/ml) may
prevent excessive activation of NF-κB and proteasome
pathways, ultimately decreasing proteolysis. Taken to-
gether, CLE may be able to decrease tissue wasting through
the down regulation of pro-inflammatory cytokine levels.
The immunosuppressive and anti-inflammatory cyto-
kine IL-10, inhibits tumour development, tumour progres-
sion, modulates apoptosis and suppresses angiogenesis
during tumour regression [1, 3]. Additionally, IL-10 in-
hibits NF-κB activation and subsequently inhibits pro-
inflammatory cytokine production (TNF-α, and IL-6) [3].
With regard to tissue wasting, increased IL-10 levels in
colon 26- bearing mice was reported to reverse the
cachectic syndrome [47]. The decreased PBMC IL-10
concentration may be due to IL-10 combating increased
pro-inflammatory cytokine levels (IL-6 and IL-1β). In
THP-1 cells, the potential of CLE to increase IL-10 levels
will facilitate a decrease in pro-inflammatory cytokine
levels, a decrease in malignant cell progression and pos-
sibly alleviate the cancer cachectic syndrome.
GSH, a potent antioxidant [48], effectively scavenges
ROS both directly and indirectly [49]. In PBMC’s and
THP-1 cells, CLE increased GSH concentrations. At 72 h,
CLE (0.4 mg/ml) increased GSH levels more significantly
in PBMC’s (1.45-fold) than THP-1 cells (1.11-fold). This
suggests that CLE induces a higher antioxidant defense in
normal PBMC’s than cancerous THP-1 cells at 72 h.
Apoptosis is a tightly regulated process involving a
number of check points before an irreversible point is
reached [50]. The extrinsic (death receptors) and intrin-
sic (mitochondria) pathways are the two main apoptotic
pathways [26]. Activation of initiator caspases (−8, −9)
Table 3 Modulation of caspase (−8, −9, −3/7) activities and ATP levels in 24 h CLE treated THP-1 cells
CLE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 8.517 ± 0.001 1.933 ± 0.012 9.980 ± 0.008 17.551 ± 0.088
0.05 11.494 ± 0.006*** 0.415 ± 0.002*** 10.348 ± 0.218** 12.507 ± 0.398***
0.2 18.909 ± 0.085*** 0.675 ± 0.001*** 3.974 ± 0.001*** 15.586 ± 0.215***
0.4 12.276 ± 0.028*** 1.119 ± 0.003*** 4.046 ± 0.033*** 3.948 ± 0.042***
0.8 16.191 ± 0.013*** 2.261 ± 0.002*** 18.189 ± 0.104*** 19.496 ± 0.267***
(Values expressed as mean ± SD, **p < 0.001, ***p < 0.0001 compared to the control)
Table 4 Modulation of caspase (−8, −9, −3/7) activities and ATP levels in 72 h CLE treated PBMC’s
CLE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 30.688 ± 0.006 83.054 ± 0.009 132.624 ± 0.118 14.567 ± 0.184
0.05 21.726 ± 0.015*** 56.070 ± 0.003*** 128.471 ± 0.253*** 4.061 ± 0.014***
0.2 10.436 ± 0.021*** 25.014 ± 0.007*** 57.946 ± 0.024*** 2.343 ± 0.029***
0.4 42.625 ± 0.003*** 11.887 ± 0.005*** 35.842 ± 0.036*** 0.855 ± 0.002***
0.8 14.157 ± 0.045*** 32.499 ± 0.288*** 43.376 ± 0.028*** 3.117 ± 0.007***
(Values expressed as mean ± SD, ***p < 0.0001 compared to the control)
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leads to the activation of execution caspase-3/7 resulting
in activation of cytoplasmic endonucleases [26].
Previous studies reported that asiatic acid decreased
cell viability, induced apoptosis and DNA fragmenta-
tion [51, 52]. In PBMC’s, CLE (0.4–0.8 mg/ml, 24 h) de-
creased caspase-8 activity. An increase in TNF-α levels
initiates the extrinsic apoptotic pathway subsequently
activating caspase-8. However, CLE decreased PBMC
TNF-α levels which may have contributed to the de-
creased caspase-8 activity. At 24 h, CLE increased PBMC
caspase (−8 (0.05–0.2 mg/ml), −9, −3/7 (0.05–0.8 mg/ml))
activities, suggesting the activation of the extrinsic and in-
trinsic apoptotic pathways. GSH regulates apoptosis by
preventing ROS accumulation [53]. Previous studies have
demonstrated that elevated GSH levels have been associ-
ated with resistance to apoptosis [54, 55]. In PBMC’s, the
decrease in GSH levels and the increase in caspase (−9,
−3/7) activities by CLE (0.4–0.8 mg/ml, 24 h) may have
increased apoptosis ultimately decreasing PBMC cell
viability. In THP-1 cells, CLE (0.05–0.4 mg/ml) increased
caspase-8 activity and decreased caspase-9 activity, sug-
gesting initiation of apoptosis through the extrinsic path-
way (24 h). In CLE treated THP-1 cells, the decreased
caspase-9 activity may have been a consequence of the
increased GSH levels. Although extrinsic apoptosis was
activated in THP-1 cells, CLE (0.2–0.4 mg/ml) decreased
caspase-3/7 activity, indicating that apoptosis was not fully
executed (24 h). Interestingly, CLE increased THP-1 cas-
pase (−8, −9, −3/7) activities at 0.8 mg/ml (24 h), suggest-
ing an increased initiation and execution of THP-1
apoptosis.
At 72 h, caspase activities were decreased in both cell
lines, suggesting a decreased activation of apoptosis. In
PBMC’s and THP-1 cells, the increase in GSH levels and
the decrease in caspase (−9, −3/7) activities by CLE
(0.05–0.8 mg/ml, 72 h) may have decreased apoptotic
cell death. However, PBMC and THP-1 cell viability was
deceased at 0.4–0.8 mg/ml CLE and 0.8 mg/ml CLE re-
spectively, suggesting an alternative form of cell death
occurred.
Increased caspase-3 and proteasome activity, as well as
E3 ubiquitin-conjugating enzyme expression are associ-
ated with increased proteolysis [56]. Thus the ability of
CLE to down regulate caspase activities in PBMC’s and
THP-1 cells may decrease proteolysis and the progres-
sion of cancer cachexia.
The cachectic syndrome is characterized by a negative
energy balance due to reduced food intake and abnormal
metabolism [57]. The inability to ingest/ use nutrients
[5] and the negative energy balance present in cachectic
patients leads to catalysis of muscle and fat stores for
energy production [58]. In PBMC’s, CLE decreased ATP
levels, a possible consequence of the decreased cell viabil-
ity. Cancer cells require high levels of ATP for cellular
proliferation [59]. In THP-1 cells, CLE decreased ATP
levels which may decrease THP-1 cell proliferation. How-
ever in cachexia, a decrease in ATP levels may contribute
to tissue wasting.
The potent feeding stimulant neuropeptide Y (NPY)
promotes food and energy intake [60]. Increased cyto-
kine (IL-1, IL-6, TNF-α) levels may inhibit NPY signal-
ling leading to decreased food intake and increased
energy expenditure [60]. Leptin functions as a suppres-
ser of food intake and stimulator of energy consumption
[6]. Pro-inflammatory cytokines may inhibit feeding by
mimicking the hypothalamic negative-feedback signal-
ling effect of leptin [61]. Thus, the ability of CLE to
decrease pro-inflammatory cytokine levels may increase
food intake, decrease energy expenditure and possibly
combat the negative energy balance associated with can-
cer cachexia.
Conclusion
Our results show that CLE increased oxidant scavenging
activity and GSH levels, modulated pro-inflammatory
cytokine levels and regulated apoptosis and caspase
activity in normal PBMC’s and THP-1 cells. CLE may
thus be effective in cancer cachexia.
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